Real World Objectively Measured Productivity Losses of Employees with Migraines and the Use of Calcitonin Gene-Related Peptide Inhibitors (CGRPis) in United States Employees Oct 2, 2024
Characterizing Use and Productivity Losses Among United States Employees with Migraines Using Calcitonin Gene-Related Peptide inhibitors (CGRPis): 2017-2022 Oct 2, 2024
Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines Aug 2, 2022
Comparing Self-Reported Presenteeism with Objectively Measured Direct and Indirect Costs, Lost Time and Comorbidity Assessments for Employees with Headaches and Migraines Apr 22, 2022
Absence Benefit Utilization, Duration of Leaves, and Payments Vary By Benefit and over Time for Short- and Long-Term Disability and Workers’ Compensation for Employees with Headaches and Migraines in the United States Oct 8, 2021
